Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.08−0.27 (-4.25%)
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Cartesian Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Cartesian Therapeutics's price to sales ratio was 140.1× on Nov 10, 2026, against 9.4× a year earlier. Over the last 5 years it ranged from 1.0× to 188.7×, with a median of 5.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 140.1× | +130.5 |
| 2025 | Jan 31, 2025 | 9.6× | +0.7 |
| 2024 | Dec 31, 2024 | 8.9× | +5.8 |
| 2023 | Dec 29, 2023 | 3.1× | +1.7 |
| 2022 | Dec 30, 2022 | 1.4× | −4.2 |
| 2021 | Dec 31, 2021 | 5.6× | −23.1 |
| 2020 | Dec 31, 2020 | 28.8× | −95.1 |
| 2019 | Dec 31, 2019 | 123.9× | +59.1 |
| 2018 | Jan 31, 2018 | 64.8× | −4.8 |
| 2017 | Dec 29, 2017 | 69.6× | +26.7 |
| 2016 | Dec 30, 2016 | 42.8× | – |
See a number that looks wrong?